Axovant and Benitec estbalish gene therapy partnership
VERDICT MEDIA LIMITED | July 10, 2018
Pharmaceutical company Axovant Sciences has signed a gene therapy licensing and development deal with Australia-based Benitec Biopharma to expand its pipeline of products. Under the terms of the collaboration, Axovant will have exclusive global licensing rights to Benitec’s Silence-and-Replace gene therapy programme being developed to treat oculopharyngeal muscular dystrophy (OPMD).